在制药界,一场激烈的竞争正在上演,尤其是在糖尿病和减肥药物领域。诺和诺德(Novo Nordisk)与礼来(Eli Lilly)两家公司,自2017年Ozempic获批用于治疗2型糖尿病以来,一直在努力推出更新、更有效的GLP-1受体激动剂药物,以抢占市场先机。然而,近期诺和诺德的新药CagriSema在临床试验中的表现并未如预期般亮眼,导致其股价暴跌,市值蒸发600多亿美元。临床试验结果揭晓,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.